Quince Therapeutics, Inc. (NASDAQ:QNCX) Receives $690.00 Consensus Target Price from Brokerages

Shares of Quince Therapeutics, Inc. (NASDAQ:QNCX) have been assigned a consensus recommendation of “Hold” from the ten analysts that are presently covering the stock, MarketBeat Ratings reports. Two equities research analysts have rated the stock with a sell rating, five have assigned a hold rating, two have given a buy rating and one has issued a strong buy rating on the company. The average 12 month price objective among brokers that have issued ratings on the stock in the last year is $690.00.

QNCX has been the topic of several recent analyst reports. Zacks Research upgraded Quince Therapeutics to a “hold” rating in a research note on Wednesday, June 24th. Weiss Ratings lowered Quince Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Friday, May 1st. Wall Street Zen upgraded shares of Quince Therapeutics from a “sell” rating to a “hold” rating in a research report on Sunday, May 17th. Cantor Fitzgerald assumed coverage on Quince Therapeutics in a report on Tuesday, June 23rd. They issued an “overweight” rating and a $80.00 price target for the company. Finally, Lifesci Capital raised Quince Therapeutics to a “strong-buy” rating in a report on Monday, June 29th.

Institutional Investors Weigh In On Quince Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of QNCX. XTX Topco Ltd purchased a new stake in shares of Quince Therapeutics during the 2nd quarter valued at $37,000. Intellectus Partners LLC purchased a new position in Quince Therapeutics in the fourth quarter worth $179,000. Bridgeway Capital Management LLC increased its stake in Quince Therapeutics by 20.9% in the second quarter. Bridgeway Capital Management LLC now owns 128,617 shares of the company’s stock valued at $212,000 after acquiring an additional 22,200 shares during the last quarter. Hudson Bay Capital Management LP bought a new position in Quince Therapeutics in the fourth quarter valued at $213,000. Finally, Quadrature Capital Ltd bought a new stake in Quince Therapeutics during the fourth quarter worth about $268,000. 30.75% of the stock is owned by hedge funds and other institutional investors.

Quince Therapeutics Price Performance

NASDAQ:QNCX opened at $17.54 on Monday. The firm has a 50-day moving average of $20.66 and a 200-day moving average of $141.94. The company has a market cap of $17.19 million, a PE ratio of -0.08 and a beta of 1.40. Quince Therapeutics has a one year low of $15.10 and a one year high of $909.98.

Quince Therapeutics (NASDAQ:QNCX) last announced its quarterly earnings results on Monday, May 11th. The company reported ($0.59) earnings per share for the quarter, beating the consensus estimate of ($26.00) by $25.41. On average, equities research analysts expect that Quince Therapeutics will post -0.96 earnings per share for the current fiscal year.

About Quince Therapeutics

Quince Therapeutics, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene. Its AIDE technology platform, a drug/device combination platform that uses an automated process to encapsulate a drug into a patient's own red blood cells, as well as consists of an automated equipment the RCL, a sterile single-use consumable treatment kit comprising EryKit, Syringe Kit, drugs, and process solutions.